Relationship Between Visfatin Level and Cardiovascular Changes in Hemodialysis Patients.

Abstract

Background : Cardiovascular alterations such as atherosclerosis, calci fi cation, heart failure, diastolic and systolic dysfunction, and stroke are the primary causes of mortality in people with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Individuals with CKD have been demonstrated to have increased serum levels of visfatin. A new study suggests that high visfatin levels in individuals with CKD accurately predict cardiovascular abnormalities. Chronic renal failure, atherosclerosis, and calci fi cation in the carotid arteries vary in individuals. The researchers set out to look at the correlation of visfatin level and cardiovascular abnormalities in CKD patients. In this case e control comparative study, conventional echocardiogram and carotid duplex assessment were used to evaluate the differences between 40 patients with stage III or stage IV CKD receiving conservative treatment, 40 ESRD patients receiving regular hemodialysis, and 20 participants as a control group. Results : Hemodialysis-dependent carotid atherosclerosis, systolic and diastolic dysfunction, and calci fi cations are more common in ESRD patients compared with nonhemodialysis-dependent individuals that signi fi cantly correlated with high serum visfatin levels compared with healthy control participants. Carotid atherosclerosis, diastolic dysfunction, and systolic dysfunction are all more likely to occur in those with CKD who had increased carotid intima-media thickness ( P ¼ 0.036) of carotid Doppler, decreased EF % ( P ¼ 0.032), increased left ventricular mass index ( P ¼ 0.004), and reversed Early diastolic over late diastolic trans mitral fl ow (E/A) ratio ( P ¼ 0.003) demonstrated by echocardiographic and carotid Doppler assessment. Patients with an elevated visfatin level had increased cardiovascular morbidity and mortality and atherosclerosis of the carotid arteries with a high risk of ischemic stroke.